Defining treatment-resistant schizophrenia and response to antipsychotics: A review and recommendation

Psychiatry Research

Volumn 197, Issue 1-2, 2012, Pages 1-6

  Suzuki, Takefumi ^a   Remington, Gary ^b,c   Mulsant, Benoit H ^b,c   Uchida, Hiroyuki ^a,c   Rajji, Tarek K ^b,c   Graff Guerrero, Ariel ^b,c   Mimura, Masaru ^a   Mamo, David C ^b,c  

^a KEIO UNIVERSITY   (Japan)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Antipsychotics; Definition; Functioning; Response; Symptoms; Treatment resistant schizophrenia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; NEUROLEPTIC AGENT;

ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE SEVERITY; DRUG RESPONSE; FUNCTIONAL ASSESSMENT; HUMAN; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; SOCIAL ADAPTATION; SOCIAL DISABILITY; SOCIAL INTERACTION; SUICIDAL IDEATION; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; DATABASES, BIBLIOGRAPHIC; DRUG RESISTANCE; HUMANS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 84862828607     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.02.013     Document Type: Article

References (53)

1. Agid O., Kapur S., Arenovich T., Zipursky R.B. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Archives of General Psychiatry 2003, 60:1228-1235.
2. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. The American Journal of Psychiatry 2005, 162:441-449.
3. Azorin J.M., Spiegel R., Remington G., Vanelle J.M., Péré J.J., Giguere M., Bourdeix I. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. The American Journal of Psychiatry 2001, 158:1305-1313.
4. Baldessarini R.J., Cohen B.M., Teicher M.H. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry 1988, 45:79-91.
5. Brenner H.D., Dencker S.J., Goldstein M.J., Hubbard J.W., Keegan D.L., Kruger G., Kulhanek F., Liberman R.P., Malm U., Midha K.K. Defining treatment refractoriness in schizophrenia. Schizophrenia Bulletin 1990, 16:551-561.
6. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B.A., Himelhoch S., Fang B., Peterson E., Aquino P.R., Keller W. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin 2010, 36:71-93. Schizophrenia Patient Outcomes Research Team (PORT).
7. Ciapparelli A., Dell'Osso L., Bandettini di Poggio A., Carmassi C., Cecconi D., Fenzi M., Chiavacci M.C., Bottai M., Ramacciotti C.E., Cassano G.B. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. The Journal of Clinical Psychiatry 2003, 64:451-458.
8. Conley R.R., Carpenter W.T., Tamminga C.A. Time to clozapine response in a standardized trial. The American Journal of Psychiatry 1997, 1997(154):1243-1247.
9. Conley R.R., Tamminga C.A., Bartko J.J., Richardson C., Peszke M., Lingle J., Hegerty J., Love R., Gounaris C., Zaremba S. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. The American Journal of Psychiatry 1998, 155:914-920.
10. Conley R.R., Kelly D.L., Nelson M.W., Richardson C.M., Feldman S., Benham R., Steiner P., Yu Y., Khan I., McMullen R., Gale E., Mackowick M., Love R.C. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clinical Neuropharmacology 2005, 28:163-168.
11. Davis J.M., Chen N. Dose response and dose equivalence of antipsychotics. Journal of Clinical Psychopharmacology 2004, 24:192-208.
12. Elkis H. Treatment-resistant schizophrenia. Psychiatric Clinics of North America 2007, 30:511-533.
13. Elkis H., Meltzer H.Y. Refractory schizophrenia. Revista Brasileira de Psiquiatria 2007, 29(Suppl. 2):S41-S47.
14. Flynn S.W., MacEwan G.W., Altman S., Kopala L.C., Fredrikson D.H., Smith G.N., Honer W.G. An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry 1998, 31:25-29.
15. Gallego J.A., Robinson D.G., Sevy S.M., Napolitano B., McCormack J., Lesser M.L., Kane J.M. Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months?. The Journal of Clinical Psychiatry 2011, 72:1691-1696.
16. Gardner D.M., Murphy A.L., O'Donnell H., Centorrino F., Baldessarini R.J. International consensus study of antipsychotic dosing. The American Journal of Psychiatry 2010, 167:686-693.
17. Jäger M., Schmauss M., Laux G., Pfeiffer H., Naber D., Schmidt L.G., Gaebel W., Klosterkötter J., Heuser I., Maier W., Lemke M.R., Degner D., Buchkremer G., Gastpar M., Möller H.J., Riedel M. Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study. European Psychiatry 2009, 24:501-506.
18. Josiassen R.C., Joseph A., Kohegyi E., Stokes S., Dadvand M., Paing W.W., Shaughnessy R.A. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. The American Journal of Psychiatry 2005, 162:130-136.
19. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., López-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rössler A., Grobbee D.E. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371:1085-1097. EUFEST study group.
20. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988, 45:789-796.
21. Kane J.M., Meltzer H.Y., Carson W.H., McQuade R.D., Marcus R.N., Sanchez R. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. The Journal of Clinical Psychiatry 2007, 68:213-223. Aripiprazole Study Group.
22. Lehman A.F., Steinwachs D.M. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin 1998, 24:1-10.
23. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., Kreyenbuhl J. Practice guideline for the treatment of patients with schizophrenia, second edition. The American Journal of Psychiatry 2004, 161(2 Suppl.):1-56. American Psychiatric Association, Steering Committee on Practice GuidelinesSteering Committee on Practice Guidelines.
24. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., Engel R.R. What does the PANSS mean?. Schizophrenia Research 2005, 79:231-238.
25. Leucht S., Kane J.M., Etschel E., Kissling W., Hamann J., Engel R.R. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006, 31:2318-2325.
26. Leucht S., Busch R., Kissling W., Kane J.M. Early prediction of antipsychotic nonresponse among patients with schizophrenia. The Journal of Clinical Psychiatry 2007, 68:352-360.
27. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
28. Leucht S., Davis J.M., Engel R.R., Kissling W., Kane J.M. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatrica Scandinavica 2009, (Suppl. s438):7-14.
29. Levine S.Z., Leucht S. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biological Psychiatry 2010, 68:86-92.
30. Lieberman J.A., Safferman A.Z., Pollack S., Szymanski S., Johns C., Howard A., Kronig M., Bookstein P., Kane J.M. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. The American Journal of Psychiatry 1994, 151:1744-1752.
31. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine 2005, 353:1209-1223. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.
32. Martin J.L., Pérez V., Sacristán M., Rodríguez-Artalejo F., Martínez C., Alvarez E. Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. European Psychiatry 2006, 21:11-20.
33. Meltzer H.Y. Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Archives of General Psychiatry 1989, 46:672.
34. Meltzer H.Y., Bobo W.V., Roy A., Jayathilake K., Chen Y., Ertugrul A., Anil Yaǧcioǧlu A.E., Small J.G. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. The Journal of Clinical Psychiatry 2008, 69:274-285.
35. Moore T.A., Buchanan R.W., Buckley P.F., Chiles J.A., Conley R.R., Crismon M.L., Essock S.M., Finnerty M., Marder S.R., Miller D D., McEvoy J.P., Robinson D.G., Schooler N.R., Shon S.P., Stroup T.S., Miller A.L. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. The Journal of Clinical Psychiatry 2007, 68:1751-1762.
36. Quintero J., Barbudo del Cura E., López-Ibor M.I., López-Ibor J.J. The evolving concept of treatment-resistant schizophrenia. Actas Españolas de Psiquiatría 2011, 39:236-250.
37. Rabinowitz J., Levine S.Z., Barkai O., Davidov O. Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Schizophrenia Bulletin 2009, 35:775-788.
38. Remington G., Saha A., Chong S.A., Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005, 19:843-872.
39. Remington G., Foussias G., Agid O. Progress in defining optimal treatment outcome in schizophrenia. CNS Drugs 2010, 24:9-20.
40. Rosenheck R., Cramer J., Xu W., Thomas J., Henderson W., Frisman L., Fye C., Charney D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. The New England Journal of Medicine 1997, 337:809-815.
41. Rosenheck R.A., Krystal J.H., Lew R., Barnett P.G., Fiore L., Valley D., Thwin S.S., Vertrees J.E., Liang M.H. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. The New England Journal of Medicine 2011, 364:842-851. CSP555 Research Group.
42. Sacchetti E., Galluzzo A., Valsecchi P., Romeo F., Gorini B., Warrington L. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophrenia Research 2009, 113:112-121. MOZART Study Group.
43. Suzuki T. Which rating scales are regarded as 'the standard' in clinical trials for schizophrenia? A critical review. Psychopharmacology Bulletin 2011, 44:18-31.
44. Suzuki T., Uchida H., Nomura K., Takeuchi H., Nakajima S., Tanabe A., Yagi G., Watanabe K., Kashima H. Novel rating scales for schizophrenia - Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz). Schizophrenia Research 2008, 106:328-336.
45. Suzuki T., Uchida H., Takeuchi H., Nakajima S., Nomura K., Tanabe A., Yagi G., Watanabe K., Kashima H. Augmentation of atypical antipsychotics with valproic acid. An open-label study for difficult-to-treat patients with schizophrenia. Human Psychopharmacology 2009, 24:628-638.
46. Suzuki T., Takeuchi H., Nakajima S., Nomura K., Uchida H., Yagi G., Watanabe K., Kashima H. Magnitude of rater differences in assessment scales for schizophrenia. Journal of Clinical Psychopharmacology 2010, 30:607-611.
47. Suzuki T., Remington G., Arenovich T., Uchida H., Agid O., Graff-Guerrero A., Mamo D.C. Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia. The British Journal of Psychiatry 2011, 199:275-280.
48. Suzuki T., Remington G., Mulsant B.H., Rajji T.K., Uchida H., Graff-Guerrero A., Mamo D.C. Defining treatment resistant schizophrenia and response to antipsychotics: review on the definitions. Schizophrenia Research 2011, 133:54-62.
49. Suzuki T., Remington G., Uchida H., Rajji T.K., Graff-Guerrero A., Mamo D.C. Management of schizophrenia in late-life with antipsychotic medications: a qualitative review. Drugs & Aging 2011, 28:961-980.
50. Tollefson G.D., Birkett M.A., Kiesler G.M., Wood A.J. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biological Psychiatry 2001, 49:52-63. Lilly Resistant Schizophrenia Study Group.
51. Uchida H., Takeuchi H., Graff-Guerrero A., Suzuki T., Watanabe K., Mamo D.C. Predicting dopamine D[U+2082] receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. Journal of Clinical Psychopharmacology 2011, 31:318-325.
52. Uchida H., Takeuchi H., Graff-Guerrero A., Suzuki T., Watanabe K., Mamo D.C. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. Journal of Clinical Psychopharmacology 2011, 31:497-502.
53. Volavka J., Czobor P., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J.P., Cooper T.B., Chakos M., Lieberman J.A. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. The American Journal of Psychiatry 2002, 159:255-262.